A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesity
As a result, patients often experience a reduction in hunger and an increase in feelings of fullness, leading to a decrease in overall caloric intake
The authors describe the high clinical benefit rate in their cohort as a clarion call for rigorous, systematic investigation, but thus far there has been no large-scale or prospective, controlled investigation for MCAS
Common Hepaglide 0.25 mg injection side effects are: Nausea or vomiting Diarrhea or constipation Abdominal pain or bloating Headache Injection site reactions, such as redness, swelling, or irritation Fatigue or dizziness Safety Advice Liver Disease There is limited information regarding the use of Hepaglide 0.25 mg in patients with liver disease
Long-term efficacy trajectories of GLP-1 receptor agonists: a systematic review and network meta-analysis, Diabetes, Metabolic Syndrome and Obesity (2025) The effect of early response to GLP-1 RA therapy on long-term adherence and persistence among Type 2 diabetes patients in the United States, Journal of Managed Care & Specialty Pharmacy (2019) Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: A systematic review and meta-analysis, Obesity (2022) FDA approves first medication for obstructive sleep apnea, U.S
The article treats these as the behaviors built during treatment that have to continue afterward, rather than as something introduced only once the medication stops
